Gulati G, Tjessem KH, Horndalsveen H, Halvorsen S, Haakensen VD. Sjekkpunkthemmerindusert myokarditt.
TIDSSKRIFT FOR DEN NORSKE LEGEFORENING 2022;
142:21-0817. [PMID:
36511752 DOI:
10.4045/tidsskr.21.0817]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Immunological checkpoint inhibitors have been revolutionary in the treatment of cancer. A rare but serious adverse effect is the development of heart muscle inflammation (myocarditis). The prevalence of this type of myocarditis is increasing as more cancer patients receive treatment with immune checkpoint inhibitors. Knowledge of immune checkpoint inhibitor-induced myocarditis is important to enable early diagnosis and initiation of treatment. In this article we provide a clinical review of this.
Collapse